牛牛AI助理已提取核心訊息
Tonix Pharmaceuticals Holding Corp. reported an amendment to its Schedule 13G/A filing, indicating that Tang Capital Partners, LP, Tang Capital Management, LLC, and Kevin Tang collectively own 0 shares of the company's common stock, representing 0.0% of the class. The amendment, filed with the Securities and Exchange Commission, was dated December 31, 2023, and the information was submitted on February 14, 2024. The filing signifies that the reporting entities have ceased to be the beneficial owners of more than five percent of Tonix Pharmaceuticals' common stock. The entities involved are organized under the laws of Delaware, and Kevin Tang is a United States citizen. The filing includes a certification by Kevin Tang, stating that the shares were not acquired with the purpose of changing or influencing the control of the issuer, nor were they held in connection with any transaction having that purpose or effect.
Tonix Pharmaceuticals Holding Corp. reported an amendment to its Schedule 13G/A filing, indicating that Tang Capital Partners, LP, Tang Capital Management, LLC, and Kevin Tang collectively own 0 shares of the company's common stock, representing 0.0% of the class. The amendment, filed with the Securities and Exchange Commission, was dated December 31, 2023, and the information was submitted on February 14, 2024. The filing signifies that the reporting entities have ceased to be the beneficial owners of more than five percent of Tonix Pharmaceuticals' common stock. The entities involved are organized under the laws of Delaware, and Kevin Tang is a United States citizen. The filing includes a certification by Kevin Tang, stating that the shares were not acquired with the purpose of changing or influencing the control of the issuer, nor were they held in connection with any transaction having that purpose or effect.
Tonix Pharmicals Holding Corp. 報告了其附表13G/A申報的修正案，表明唐資本合夥人有限責任公司、唐資本管理有限責任公司和唐凱文共擁有該公司普通股的0股，佔該類別的0.0％。該修正案是向美國證券交易委員會提交的，日期爲2023年12月31日，信息於2024年2月14日提交。該文件表明，申報實體已不再是Tonix Pharmaceuticals5％以上普通股的受益所有人。所涉實體是根據特拉華州法律組建的，唐凱文是美國公民。該文件包括唐凱文的證明，表明收購這些股票的目的不是爲了改變或影響發行人的控制權，也不是與任何具有該目的或效力的交易有關而持有的。
Tonix Pharmicals Holding Corp. 報告了其附表13G/A申報的修正案，表明唐資本合夥人有限責任公司、唐資本管理有限責任公司和唐凱文共擁有該公司普通股的0股，佔該類別的0.0％。該修正案是向美國證券交易委員會提交的，日期爲2023年12月31日，信息於2024年2月14日提交。該文件表明，申報實體已不再是Tonix Pharmaceuticals5％以上普通股的受益所有人。所涉實體是根據特拉華州法律組建的，唐凱文是美國公民。該文件包括唐凱文的證明，表明收購這些股票的目的不是爲了改變或影響發行人的控制權，也不是與任何具有該目的或效力的交易有關而持有的。
有用
沒用